Skip to main content
Recall Canary
Atellica CH Enzymatic Hemoglobin A1c Assay
← Back to all recalls
MEDICAL DEVICE RECALLMODERATE

Atellica CH Enzymatic Hemoglobin A1c Assay

Siemens is recalling the Atellica CH A1c_E assay due to a risk of depressed results when used alongside the RCRP assay on the same analyzer.

What to do

Review your laboratory workflow to determine if A1c_E and RCRP assays are being processed on the same analyzer. If they are, discontinue this practice immediately and process these assays on separate analyzers. Monitor Quality Control results for negative trends or increased imprecision.

Posted
Updated
Recall No.
Z-1657-2026
Agency
Firm
Siemens Healthcare Diagnostics, Inc.
Recall ID
98498
Status
ONGOING

Why it was recalled

Siemens Healthcare Diagnostics is recalling the Atellica CH Enzymatic Hemoglobin A1c (A1c_E) assay because processing it on the same analyzer as the Atellica CH RCRP assay can cause depressed results. This negative bias and increased imprecision may lead to delayed diabetes diagnosis or suboptimal treatment. The product was distributed nationwide.

Is mine affected?

Check the model, lot, or serial number on the device or its packaging. Yours is affected if it matches one below.

Atellica CH Enzymatic Hemoglobin A1c (A1c_E); Siemens Material Number (SMN): 11097536;

UPC
11097536, 00630414220505
Recall #
Z-1657-2026

Where it was sold

Distributed nationwide.

Other recent recalls from Siemens Healthcare Diagnostics, Inc.

← Back to all recalls

Editorial summary by Recall Canary · last updated 2026-06-11 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification